ArticleThe Lancet regional health. Europe2022
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.
Article in The Lancet regional health. Europe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- A comprehensive analysis of lung cancer status changes over 10 years: results of Moroccan cohort.BJC reports · 2026Article
- Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.Future oncology (London, England) · 2026Review
- Lung cancer screening in Lithuania: a cost-effectiveness analysis.Journal of comparative effectiveness research · 2026Article
- Impact of lung cancer discovery mode on cancer outcomes: data from the KBP-2020-CPHG study.ERJ open research · 2026Article
- Predictive value of folate receptor-positive circulating tumor cells in postoperative progressive disease of non-small cell lung cancer patients.Journal of cancer research and clinical oncology · 2026Article
- Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Intracardiac Extension of Lung Carcinoma Presenting as an Atrial Myxoma: A Case Report.Clinical case reports · 2026Article
- Systemic inflammatory indices as accessible biomarkers for intracranial outcome and prognosis in driver gene-negative NSCLC with brain metastases treated with first-line chemoimmunotherapy.Discover oncology · 2026Article
- Will We Need a Novel Heuristic in Resectable Lung Cancer?: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- Lung cancer screening for never smokers: current evidence and future directions.Singapore medical journal · 2026Review
- High prevalence of targetable drivers but poor outcomes in lung adenocarcinoma: a real-world cohort from the French West Indies.Frontiers in oncology · 2026Article
- Bridging the lung cancer screening eligibility gap: evaluation of guideline applicability in asymptomatic patients.Military Medical Research · 2026Observational
- Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer.International journal of cancer · 2025Article
- Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.JTO clinical and research reports · 2025Article
- Severe hemoptysis: etiologies, management, and outcomes from a single-center experience over the last decade.Annals of intensive care · 2025Article
- Evaluating breast cancer screening performance without registries using medico-administrative data.Scientific reports · 2025Article
- Article
- Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany.BMC pulmonary medicine · 2025Article
- Diagnosis of lung cancer using salivary miRNAs expression and clinical characteristics.BMC pulmonary medicine · 2025Article
- Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort. Methods: KBP-2020 was a prospective cohort that included all patients diagnosed with LC in 2020, in nonacademic public hospital in France. Patient and tumour characteristics were described and compared with similarly designed cohorts in 2000 and 2010. Findings: In 2020, 82 centers included 8,999 patients diagnosed with LC. The proportion of women increased: 34·6% (3114/8999) compared to, 24·3% (1711/7051) and 16·0% (904/5667) in 2010 and 2000 ( Interpretation: To our knowledge KBP cohorts have been the largest, prospective, real-world cohort studies involving LC patients conducted in worldwide. The trend found in our study shows an increase in LC in women and still a large proportion of patients diagnosed at metastatic or disseminated stage. Funding: The study was promoted by the French College of General Hospital Pulmonologists with financial support of industrials laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.